Total trials
1,789
Active
390
Phase 3
87
Total enrollment
6,441,498
Pipeline matrix
Showing 40 of 157 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Methylphenidate | — | — | — | 5 | |||
| Placebos | — | — | — | 5 | |||
| Nicotine Replacement Product | — | — | — | — | — | 3 | |
| Acetaminophen | — | — | — | — | 2 | ||
| Ublituximab | — | — | — | — | 2 | ||
| Dapagliflozin 10mg Tab | — | — | — | — | — | 1 | |
| Transdermal estrogen | — | — | — | — | — | 1 | |
| Progesterone | — | — | — | — | — | 1 | |
| AbobotulinumtoxinA | — | — | — | — | — | 1 | |
| Dupilumab - Discontinuation | — | — | — | — | — | 1 | |
| Dupilumab - Dose Reduction | — | — | — | — | — | 1 | |
| Dupilumab - Standard Dose | — | — | — | — | — | 1 | |
| Elucirem | — | — | — | — | — | 1 | |
| sertraline 50 mg daily | — | — | — | — | — | 1 | |
| Ibuprofen | — | — | — | — | — | 1 | |
| Oxycodone | — | — | — | — | — | 1 | |
| Osilodrostat | — | — | — | — | — | 1 | |
| Ocrelizumab | — | — | — | — | 4 | ||
| Tacrolimus | — | — | — | — | — | 4 | |
| Cannabidiol | — | — | — | — | 2 | ||
| Rifampin | — | — | — | 6 | |||
| Varenicline | — | — | — | 3 | |||
| Moxifloxacin | — | — | — | 3 | |||
| Nicotine gum | — | — | — | — | 2 | ||
| Nicotine patch | — | — | — | — | 2 | ||
| Rifapentine | — | — | — | — | 2 | ||
| Pyrazinamide | — | — | — | — | 2 | ||
| Ethambutol | — | — | — | — | 2 | ||
| Isoniazid | — | — | — | — | 2 | ||
| Cysview | — | — | — | — | — | 1 | |
| Emetine Hydrochloride 6mg | — | — | — | — | — | 1 | |
| Emetine Hydrochloride 12mg | — | — | — | — | — | 1 | |
| Continuous DOAC therapy | — | — | — | — | — | 1 | |
| Naloxone Nasal Spray | — | — | — | — | — | 1 | |
| Secretin | — | — | — | — | — | 1 | |
| Triamcinolone 0.1% | — | — | — | — | — | 1 | |
| Aspirin 81mg | — | — | — | — | — | 1 | |
| Aspirin 162 mg | — | — | — | — | — | 1 | |
| Aspirin 325mg | — | — | — | — | — | 1 | |
| Dolutegravir 50mg Tab | — | — | — | — | — | 1 |
117 more active programs hidden
Next readouts
- 2025-03-01
- 2025-05-06
- 2025-12
- 2026-01-01
- 2026-03-02
- 2026-03-09
- 2026-05-21
- 2026-06
- 2026-06-25
- 2026-06-26
Top conditions
- Hypertension40
- Obesity32
- Asthma29
- HIV28
- Depression26
- HIV Infections24
- Healthy22
- Tuberculosis22
Frequently asked questions about Johns Hopkins University
- How many clinical trials does Johns Hopkins University have on ClinicalTrials.gov?
- Johns Hopkins University is listed as the lead sponsor on 1,789 clinical trials in ClinicalTrials.gov, 390 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Johns Hopkins University's trials are in Phase 3?
- 87 of Johns Hopkins University's trials are in Phase 3, spread across 157 active drug programs.
- What therapeutic areas does Johns Hopkins University focus on?
- Johns Hopkins University's most-studied conditions on ClinicalTrials.gov are Hypertension, Obesity, Asthma, HIV, Depression.
- When are Johns Hopkins University's next clinical trial readouts?
- Johns Hopkins University has 10 upcoming primary-completion readouts tracked here; the soonest is “Effect of Topical Sulforaphane on Skin Aging and With Ultraviolet and Visible Light Exposure”, expected around 2025-03-01.